Eye drop vs. pill: race to stop a virus that steals sight

NCT ID NCT03586284

Summary

This study aimed to find the best way to treat a painful and potentially blinding eye infection called cytomegalovirus (CMV) anterior uveitis. It compared an oral antiviral pill (valganciclovir) against an antiviral eye drop (ganciclovir 2%) and a placebo in 51 adults with a confirmed diagnosis. The goal was to see which treatment most effectively reduced the amount of virus in the eye and controlled the inflammation.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS ANTERIOR UVEITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Chiang Mai University

    Chiang Mai, Thailand

  • Chulalongkorn University

    Bangkok, Thailand

  • Khon Kaen University

    Khon Kaen, Thailand

  • Proctor Foundation, UCSF

    San Francisco, California, 94158, United States

Conditions

Explore the condition pages connected to this study.